Siren LLC’s Akero Therapeutics AKRO Stock Holding History

Siren LLC’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-318,647	Closed	-$17M	–	116
2025 Q2	$17M	Buy	+318,647	New	+$14.5M	0.88%	31

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC's AKRO Position: Q3 2025 in Review

Siren LLC sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 318,647 shares — an estimated $17M sold.

Siren LLC first reported a position in AKRO in Q2 2025 and held it in 1 quarter. The position peaked at $17M in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

Siren LLC reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
Siren LLC sold 318,647 Akero Therapeutics shares in Q3 2025, an estimated $17M.
Siren LLC first reported a position in Akero Therapeutics in Q2 2025 and held it in 1 quarter.
Siren LLC's Akero Therapeutics position peaked at $17M in Q2 2025.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Siren LLC's 13F filing for Q3 2025, filed 13 Nov 2025.